(continued)

Date: May 2014

Ref: UK/CPE/14/0049

For immediate release

Teva adds oxycodone (Oxylan®) Prolonged Release (PR) Tablets to generics portfolio

We are pleased to announce the successful launch of oxycodone PR tablets to our portfolio of generic medicine.

Indicated for the treatment of severe pain, which requires opioid analgesics to be adequately managed,

oxycodone tablets are a generic version of OxyContin® (oxycodone) from Napp. They are available to order immediately from Teva in Lannacher livery with Teva barcodes, as follows:

Oxycodone
Strength / 5mg / 10mg / 20mg / 40mg / 80mg
Pack size / 28 x tablets / 56 x tablets / 56 x tablets / 56 x tablets / 56 x tablets
PL Number / 17049/0009 / 17409/0010 / 17409/0011 / 17049/0012 / 17049/0013

Paul Burden, Interim Commercial Director said: “We are delighted to be able to add oxycodone tablets to our portfolio, and to demonstrate our ongoing commitment to pharmacy.”

New or existing customers can order through a Teva Territory Sales Manager, their wholesaler, or call 0800 085 8621.

For more information, visit www.tevauk.com.

-ENDS-

For media enquiries, contact the Teva UK Limited Communications team on 01977 628500, or email .

Notes to Editors:

About Teva UK Limited

Teva UK Limited is one of the UK’s top ten pharmaceutical manufacturers, with a presence in the generics, branded respiratory, CNS and hospitals markets. It has the widest range of any UK generic pharmaceutical company and markets solid and liquid dose, injectable and respiratory medicines to healthcare professionals. The company is part of Teva Pharmaceutical Industries Ltd.

About Teva Pharmaceutical Industries Ltd

Teva Pharmaceutical Industries Ltd. (NYSE: TEVA) is a leading global pharmaceutical company, committed to increasing access to high-quality healthcare by developing, producing and marketing affordable generic drugs as well as innovative and specialty pharmaceuticals and active pharmaceutical ingredients. Headquartered in Israel, Teva is the world's leading generic drug maker, with a global product portfolio of more than 1,000 molecules and a direct presence in about 60 countries. Teva's Specialty Medicines businesses focus on CNS, respiratory oncology, pain, and women's health therapeutic areas as well as biologics. Teva currently employs approximately 45,000 people around the world and reached $20.3 billion in net revenues in 2013.

Date of Preparation: May 2014, Job code: UK/CPE/14/0049

Teva UK Limited, Whistler Drive, Castleford WF10 5HX 01977 628500 www.tevauk.com